Mayo Collaborative Services v. Prometheus Laboratories, Inc.

AI Revolutionizes Non-Alcoholic Steatohepatitis (NASH) Diagnosis and Treatment, Fueling Impressive 53.49% CAGR - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023

The global Non-Alcoholic Steatohepatitis (NASH) market is poised to achieve a market value of US$2.71 billion by 2023, demonstrating an impressive Compound Annual Growth Rate (CAGR) of 53.49% over the projected period.

Key Points: 
  • The global Non-Alcoholic Steatohepatitis (NASH) market is poised to achieve a market value of US$2.71 billion by 2023, demonstrating an impressive Compound Annual Growth Rate (CAGR) of 53.49% over the projected period.
  • NASH, often referred to as "Silent Liver Disease," is a liver disorder caused by long-term alcohol abuse but mainly impacts non-alcoholics.
  • It is the second stage of Non-Alcoholic Fatty Liver Disease (NAFLD), marked by liver inflammation and cell damage.
  • As a result, there was an increased demand for NASH treatment, diagnostic tools, and emerging drugs, positively impacting the market.

Animal Health Diagnostics Market is to grow by USD 1.96 billion from 2022 to 2027- Technavio

Retrieved on: 
Wednesday, November 8, 2023

NEW YORK, Nov. 8, 2023 /PRNewswire/ -- The animal health diagnostics market is expected to grow by USD 1.96 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Nov. 8, 2023 /PRNewswire/ -- The animal health diagnostics market is expected to grow by USD 1.96 billion from 2022 to 2027.
  • The growing preference for health monitors is a major trend in the global animal health diagnostics market.
  • Detailed information on factors that will drive the growth of the animal health diagnostics market between 2022 and 2027.
  • Growth of the animal health diagnostics market in North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of animal health diagnostics market companies.

Masimo Announces New Member of the Board of Directors

Retrieved on: 
Tuesday, November 7, 2023

Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been appointed to Masimo’s Board of Directors.

Key Points: 
  • Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been appointed to Masimo’s Board of Directors.
  • Mr. Classon is an experienced medical technology executive and board member.
  • Mr. Classon was previously Chairman of the Board of Directors of Perrigo Company plc, Chairman of the Board of Directors of Tecan Group Ltd., Chairman of the Board of Directors of Hill-Rom Corporation, and Chairman of the Board of Directors of Auxilium Pharmaceuticals, Inc.
  • Joe Kiani, Chairman and CEO of Masimo, said, “We’re happy to welcome Rolf to our Board.

Aptatek BioSciences, Inc. Appoints Seasoned Healthcare Executive Lee McCracken to its Board of Directors

Retrieved on: 
Wednesday, November 1, 2023

Aptatek BioSciences, Inc. , a developer of pioneering home monitoring tools for chronic disease patients, has appointed Drawbridge Health Chairperson Lee McCracken as a non-executive director.

Key Points: 
  • Aptatek BioSciences, Inc. , a developer of pioneering home monitoring tools for chronic disease patients, has appointed Drawbridge Health Chairperson Lee McCracken as a non-executive director.
  • He joins Ali Tinazli, PhD, CEO of Lifespin Health, as part of the growing team of highly experienced industry professionals on Aptatek’s board of directors.
  • Lee is Chairperson of Drawbridge Health, where he was previously recruited as CEO by GE Ventures and GE Healthcare.
  • For more information about Aptatek BioSciences and its innovative home monitoring solutions, please visit Aptatek BioSciences, Inc.

Mitel Closes on Transaction with Atos to Acquire Unify

Retrieved on: 
Monday, October 2, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231002691068/en/
    Together with Unify, Mitel now has a combined customer base of more than 75M users in over 100 countries.
  • Tarun Loomba, president and chief executive officer of Mitel, will serve as President and Chief Executive Officer of the combined company.
  • “This is a transformative milestone for the Mitel and Unify teams and for the broader communication and collaboration industry," said Mitel president and CEO Tarun Loomba.
  • Resellers and strategic technology partners of Mitel and Unify can expect a similarly smooth transition, with little to no change anticipated this year.

Investment in Employee Experience, Cloud and AI Drives Improved Customer Experience, New NTT Report Shows

Retrieved on: 
Thursday, June 22, 2023

At the same time, employee experience (EX) has risen in importance to become a top-3 priority for CEOs.

Key Points: 
  • At the same time, employee experience (EX) has risen in importance to become a top-3 priority for CEOs.
  • The report found that the majority of CEOs agree that improvements in CX (92%) and EX (91%) will directly affect their net profit.
  • Cloud-based technologies and AI, automation and machine learning feature prominently in these top performers’ CX and EX strategies.
  • Top performers are already prioritizing AI, whereas it remains part of a three-year plan for most other organizations.

Mindera Health™ Announces Change to Executive Leadership Team

Retrieved on: 
Thursday, May 11, 2023

San Diego, CA, May 11, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of Mind.Px™, the first realization of precision medicine in psoriasis, has announced a change in its executive leadership team.

Key Points: 
  • San Diego, CA, May 11, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of Mind.Px™, the first realization of precision medicine in psoriasis, has announced a change in its executive leadership team.
  • The company has announced industry veteran Ron Rocca will succeed George Mahaffey as President and Chief Executive Officer.
  • Mr. Mahaffey, who joined the company in 2020, helped lead the company’s transition from the R&D stage through the commercial launch of Mindera Health’s first test.
  • “On behalf of the board, I want to thank George for his valuable contributions to Mindera Health,” said Joe Cook, III, Chairman of Mindera Health and Co-Founder and Managing Director of Mountain Group Partners.

Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed

Retrieved on: 
Wednesday, March 8, 2023

IRVINE, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced the launch of its InFoods® IBS test.

Key Points: 
  • IRVINE, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced the launch of its InFoods® IBS test.
  • The test is being performed in a CLIA-certified, and CAP accredited high-complexity laboratory facility and offered as a laboratory developed test (LDT).
  • The Company further announced all validation testing necessary for the InFoods IBS product to be offered as an LDT has been completed.
  • Mr. Robert Carlson is managing the InFoods IBS LDT launch as well as the future phases of the commercialization strategy including national reimbursement and FDA marketing authorization.

HDI Announces 2023 Strategic Advisory Board

Retrieved on: 
Tuesday, February 28, 2023

HDI , the leading organization dedicated to elevating service and support across the enterprise, today unveils its 2023 Strategic Advisory Board, comprised of industry thought leaders, senior-level practitioners, and solution providers.

Key Points: 
  • HDI , the leading organization dedicated to elevating service and support across the enterprise, today unveils its 2023 Strategic Advisory Board, comprised of industry thought leaders, senior-level practitioners, and solution providers.
  • The Strategic Advisory Board helps HDI stay abreast of customer insights and support center and service management market developments.
  • Our Strategic Advisory Board members continue to help us deliver best-in-class industry insights.
  • For inquiries regarding the Strategic Advisory Board, contact Tara Gibb at [email protected] .

Global TIL Therapies Market Report 2023 to 2035: Key Players Include Bristol-Myers Squibb, CAR-T (Shanghai) Cell Biotechnology, Cellectis and Incyte - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 1, 2023

The "Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.
  • The report features an extensive study of the current market landscape and future opportunity for the players focused on the development of TIL therapies.
  • This report features an extensive study of the current market landscape and future opportunity for the players focused on the development of TIL therapies.
  • Overall, we are led to believe that the global TIL therapies market is poised to witness significant growth in the foreseen future.